

Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?

Eldad J. Dann

Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Correspondence: E.J. Dann
e_dann@rambam.health.gov.il

Received: November 18, 2025.

Accepted: February 17, 2026.

Early view: February 26, 2026.

<https://doi.org/10.3324/haematol.2025.289210>

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



The treatment of Hodgkin lymphoma (HL) has dramatically advanced over the past two decades, facilitating deep and durable responses, with the current 4-year progression-free survival (PFS) being close to 90%. Given that the median age of HL patients is 32 years, their post-treatment life expectancy nowadays reaches five decades, which makes the issue of late toxicity crucial. It has been demonstrated that 2–3 decades after the end of treatment, cardiac morbidity becomes the dominant problem.^{1,2} Moreover, it has been established that the most prevalent non-malignant cause of death in HL survivors is cardiac.^{3,4} The estimated relative risk (RR) of cardiac mortality at 15–20 years of follow-up range between 2.8–6.8, whereas absolute excess risks vary between 12.3–54/10,000 person-years of follow-up.³ While analyses performed 15–30 years after completing therapy do provide data on long-term toxicity, this information may be not entirely pertinent to the current therapeutic approaches. For instance, the awareness of the radiation therapy (RT) toll on the incidence of secondary malignancies and cardiac disease has led to profound changes in RT techniques, the dosage used, and the radiation field size, which has changed from the mantle field to involved-site or involved nodal RT, performed using intensity-modulated RT. These modifications have resulted in a 90% reduction in cardiac exposure to RT.⁴

In this issue of *Haematologica*, Marr *et al.* from the British Columbia Cancer Center present interesting findings on 804 adolescent and young adult HL patients, aged 15–39 years during treatment, who have been followed for 15–30 years.¹ The cumulative incidence of cardiovascular disease in this cohort was compared to that documented in the British Columbia general population registry. The heart failure (HF) rate among HL survivors was 4.3% *versus* 0.8% in the control group, with the corresponding values of ischemic heart disease (IHD) amounting to 8.3% *versus* 2.8%, respectively. The RR of combined cardiovascular disease was 2.88, while RR was 5.18 for HF and 2.38 for IHD. Notably,

the RR of HF was particularly increased in patients carrying comorbidities, including diabetes mellitus, hypertension or chronic obstructive pulmonary disease (COPD) (3.34, 3.09, 5.8, respectively). These findings emphasize the need for long-term and aggressive treatment of the aforementioned comorbidities in this patient population, incurring increased HF and IHD risk 2–3 decades after therapy. Another key finding is the reduction in IHD RR owing to the introduction of PET/CT-guided therapeutic approaches, applying RT only to patients with positive interim PET (PET-2). These modifications have resulted in a significant decrease in the percentage of patients exposed to RT (from 56% to 14.9%). Consequently, IHD rates in these patients have dramatically declined, while there is no significant difference in RR from that observed in the control group.

On the other hand, no changes in the HF pattern have been demonstrated (see Marr *et al.*, Figure 3C1), which highlights the need for further cardiotoxicity reductions in these patients. Nowadays, the backbone of HL therapy is still based on the adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine (ABVD) regimen, introduced by the late Dr. Gianni Bonadonna in the 1970s, with several modifications implemented later to reduce bleomycin-related pulmonary toxicity.⁵ In a recent randomized ECHELON-1 trial, demonstrating improved PFS and OS, patients with advanced-stage HL were treated with the regimen containing brentuximab vedotin (A-AVD) instead of bleomycin (ABVD).⁶ Treatment in another randomized study, S1826, that recruited patients aged ≥12 years with stage III–IV HL, was also based on the AVD backbone with an addition of the immune checkpoint inhibitor nivolumab (Nivo-AVD) in one arm and A-AVD in the other.⁷ Notably, Nivo-AVD was associated with significantly improved 24-month PFS. However, as specified in the article by Marr *et al.*, in both these pivotal studies, patients continued to be exposed to 300 mg/m² of adriamycin, a well-established cardiotoxic agent, the toxicity of which is dose- and age-dependent.²

Remarkably, the use of immune checkpoint inhibitors is also associated with elevated risk of cardiovascular disease, e.g., atherosclerosis⁸ and acute myocarditis.⁴ Despite the major benefits of the AVD-based therapy, late cardiotoxicity, particularly an increased rate of HF even 30 years post treatment, can take a heavy toll on these patients. Several study groups have addressed this highly important issue. In their seminal work, Engert *et al.*, from the German Hodgkin Study Group, reported a non-inferior 5-year freedom-from-treatment-failure despite the reduction in the number of ABVD cycles from 4 to 2 and in the dose of involved-field RT from 30 to 20 Gy in patients with early-stage favorable HL.⁹ For patients with advanced-stage HL, the standard of care from 1998 to 2011 was 8 cycles of escalated BEACOPP, indicating exposure to 280 mg/m² of adriamycin, while 70% also received RT. Nowadays, pa-

tients demonstrate improved results following PET-2-guided treatment with 4-6 cycles of the brentuximab vedotin-based protocol (brentuximab vedotin, etoposide, cyclophosphamide, adriamycin, dacarbazine, dexamethasone - BrECADD), which is more efficient and less toxic than BEACOPP. The majority of such patients receive a cumulative adriamycin dose of only 160 mg/m².¹⁰ One of the key questions in current HL management (Figure 1) is whether the cumulative adriamycin dose in the AVD-based therapy for patients with negative PET-2 could be safely reduced to mitigate cardiotoxicity. The emergence of novel molecular tools that are more specific than PET-2, such as the plasma cell-free DNA (ctDNA) analysis, may assist in detecting minimal residual disease (MRD), allowing for treatment adjustment and an ultimate decrease in cumulative chemotherapy dosage. One of such eagerly




Figure 1. Current first-line treatments for Hodgkin lymphoma and causes of associated cardiac damage. ABVD: adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine; BrECADD: brentuximab vedotin, etoposide, cyclophosphamide, adriamycin, dacarbazine, dexamethasone; Bv-AVD: brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; Nivo-AVD: nivolumab and AVD; IMRT-VMAT: intensity modulated radio therapy (RT)-volumetric modulated arc therapy.

anticipated studies is currently being conducted by Kurts *et al.* at the University of Washington (clinicaltrials.gov identifier NCT06745076). In this study, MRD-negative patients, both according to PET-2 and ctDNA, are randomized to a total of 4 cycles *versus* the standard 6 cycles of Nivo-AVD, which could reduce exposure to adriamycin to 200 mg/m². Another approach to decreasing myocardial and endothelial damage associated with adriamycin is the use of dexrazoxane and atorvastatins.

Overall, the present study by Marr *et al.*, along with others, provides a strong argument that the chapter of HL treatment-related cardiotoxicity remains unfinished. The fact that the 30-year risk of cardiac morbidity among HL survivors is currently predicted to be as high as 7% calls for rigorous consideration of this issue in upcoming trials.

Disclosures

No conflicts of interest to disclose.

References

1. Marr KC, Tang T, Simkin J, et al. Long-term cardiac morbidity in adolescent and young adult survivors of classic Hodgkin lymphoma in British Columbia. *Haematologica*. 2026;111(9):3019-3029.
2. Lo AC, Liu A, Liu Q, et al. Late cardiac toxic effects associated with treatment protocols for Hodgkin lymphoma in children. *JAMA Netw Open*. 2024;7(1):e2351062.
3. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. *Br J Haematol*. 2011;154(1):23-31.
4. Raman HS, Mitchell J, Nohria A, Upshaw JN, LaCasce AS. Cardiovascular and oncologic considerations in adult Hodgkin lymphoma: JACC: CardioOncology state-of-the-art review. *JACC CardioOncol*. 2025;7(7):781-799.
5. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. *N Engl J Med*. 2016;374(25):2419-2429.
6. Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. *N Engl J Med*. 2022;387(4):310-320.
7. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. *N Engl J Med*. 2024;391(15):1379-1389.
8. Barcia Durán JG, Das D, Gildea M, et al. Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors. *Nat Cardiovasc Res*. 2024;3(12):1482-1502.
9. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med*. 2010;363(7):640-652.
10. Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. *Lancet*. 2024;404(10450):341-352.